Document is current
Any future updates will be listed below
-
Authors
Chemi, Francesca https://orcid.org/0000-0002-6652-5243
Pearce, Simon P. https://orcid.org/0000-0002-1680-5538
Clipson, Alexandra https://orcid.org/0000-0002-4568-4173
Hill, Steven M.
Conway, Alicia-Marie https://orcid.org/0000-0003-2635-8206
Richardson, Sophie A. https://orcid.org/0000-0002-8101-7810
Kamieniecka, Katarzyna
Caeser, Rebecca
White, Daniel J.
Mohan, Sumitra
Foy, Victoria
Simpson, Kathryn L. https://orcid.org/0000-0002-4386-0401
Galvin, Melanie
Frese, Kristopher K.
Priest, Lynsey
Egger, Jacklynn
Kerr, Alastair https://orcid.org/0000-0001-9207-6050
Massion, Pierre P.
Poirier, John T. https://orcid.org/0000-0001-9795-5644
Brady, Gerard https://orcid.org/0000-0002-5009-8814
Blackhall, Fiona
Rothwell, Dominic G. https://orcid.org/0000-0002-8757-3893
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
Dive, Caroline https://orcid.org/0000-0002-1726-8850
-
Funding
Funding for this research was provided by:
Cancer Research UK (C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412, C5759/A25254/A20465/A27412)
DH | National Institute for Health Research (CA197936/CA263816/CA213274, CA197936/CA263816/CA213274, CA197936/CA263816/CA213274, CA197936/CA263816/CA213274, CA197936/CA263816/CA213274, CA197936/CA263816/CA213274)
- License Information
-
More Information
Article History
Received: 31 January 2022
Accepted: 28 June 2022
First Online: 8 August 2022
Competing interests
: C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, Epizyme, Genentech/Roche, Ipsen, Jazz, Lilly and Syros and serves on the scientific advisory boards of Bridge Medicines, Earli and Harpoon Therapeutics. C.D. receives research grants/support from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has received honoraria/consultancy fees from Biocartis, Merck, AstraZeneca and GRAIL. The remaining authors declare no competing interests.
